Table 2.
Clinical and demographic information on 1898 ICI-treated patients of different solid tumor types sequenced with MSK-IMPACT
|
| ||
|---|---|---|
| N (median) | % (range) | |
| Age at ICI start | 67 | 22–88 |
|
| ||
| Histology | ||
| Adenocarcinoma | 1388 | 73.1 |
| Squamous Cell Carcinoma | 236 | 12.4 |
| Non-Small Cell Lung Cancer, NOS | 132 | 7 |
| Large Cell Neuroendocrine Carcinoma | 42 | 2.2 |
| Other | 100 | 5.3 |
|
| ||
| Sex | ||
| Male | 1003 | 52.8 |
| Female | 895 | 47.2 |
|
| ||
| Site of specimen sequenced | ||
| Primary | 977 | 51.5 |
| Metastatic | 914 | 48.2 |
| Local Recurrence | 2 | 0.1 |
| Unspecified | 5 | 0.3 |
|
| ||
| Genetic Ancestry | ||
| Ashkenazi European | 325 | 17.1 |
| Non-Ashkenazi European | 1209 | 63.7 |
| East Asian | 113 | 6 |
| South Asian | 19 | 1 |
| African | 78 | 4.1 |
| Admixed/Other | 154 | 8.1 |
|
| ||
| Self-Reported Race | ||
| African Americans | 109 | 5.7 |
| Asian | 132 | 7 |
| Native American/Pacific Islander | 4 | 0.2 |
| Whites | 1556 | 82 |
| Other/Unknown | 97 | 5.1 |
|
| ||
| ICI type | ||
| Atezolizumab | 231 | 12.2 |
| Durvalumab | 146 | 7.7 |
| Ipilimumab | 58 | 3.1 |
| Nivolumab | 576 | 30.3 |
| Pembrolizumab | 887 | 46.7 |
|
| ||